Q-omics provides the consensus-scored PRDM15 profile across patient tissues and cancer cell-line models. PRDM15 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PRDM15 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, PRDM15 RNA expression shows 20,976 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where PRDM15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRDM15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRDM15 survival associations across molecular data types. PRDM15 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRDM15 RNA expression–survival associations across cancer types. High PRDM15 expression shows unfavorable associations in ACC, KIRP, MESO, COAD and LIHC, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PRDM15 RNA expression.
This table summarizes PRDM15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PRDM15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRDM15 shows higher tumor expression in HNSC, LIHC, BLCA, COAD, LUAD and KIRC. The HNSC box plot shows higher PRDM15 RNA expression in tumor versus normal tissue (log2 FC = +0.490, t-test p < 0.001).
This table shows molecular features associated with PRDM15 in patient tissues and cancer cell lines. In patient samples, PRDM15 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRDM15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
